Document is current

Article History

Received: 12 August 2025

Accepted: 5 March 2026

First Online: 20 March 2026

Declarations

:

: This trial received ethical approval from South West – Central Bristol Research Ethics Committee (22/SW/0171) on 12 December 2022. Written informed consent to participate is obtained from all participants. Written or verbal informed consent to participate in the process evaluation study is obtained from all participants and healthcare professionals.

: Not applicable as no details, images or videos relating to an individual person have been included in this publication. The template consent form (see Additional file 1), participant information leaflet (see Additional file 2) and decision-making tool supplement (see Additional file 3) are available as supplementary materials.

: AB, BC, DC, JF, NSh and RT declare that they have no competing interests. DJ, GM, LV, RH, RN and SC declare grant funding paid to the institution for this research project. SM declares participation on the NIHR HTA funded LACI-3 TSC as an academic advisor. KG declares consultancy fees for a Global Clinical Trials Panel (with payments made to the institution) from Boehringer & Ingelheim; honoraria for contribution to funding committee meetings for CRUK and MRC; participation on the NIHR HTA funded HAND2, FLARE and RIGHT TSCs; leadership or fiduciary roles on the MRC Clinical Training Panel, CRUK Population Health Panel and NIHR HTA CET Committee. GDS declares grants or contracts from AstraZeneca paid to the institution for the WIRE clinical trial; consultancy fees from Evinova for a workshop on a new product; support from MSD for attending ESMO 2023; paid roles as Associate Editor for the British Journal of Urology International and Clinical Directory (surgery) for the NATCAN National Kidney Cancer Audit; and an unpaid role as the chair of the kidney cancer pathway for Getting It Right First Time. MT declares leadership or fiduciary roles as an unpaid committee member for the NICE kidney cancer guidelines and for the European Association of Urologists Kidney Cancer guidelines. KN declares grants or contracts from Prostate Cymru, Welsh Govt Accelerate Programme, South East Wales Academic Health Science Partnership, Welsh Government Health Technology Grant, Health & Care Research Wales Research Time Award (2023–2026), and NIHR for TRAIN, ELIPSE, FOLLOW UP, TRANSLATE and for this research project; support for attending meetings as part of an NIHR grant; participation on the Quantum Tissue Biobank Oxford Advisory Board; and a private practice in Urology at Spire Cardiff Hospital including seeing patients with urological cancers and general urology conditions.